Citigroup Flags AI Drug Discovery as the Next Major Industry Catalyst, Names INSILICO Top Pick with a "Buy" Rating

Stock News09-03 17:16

Citigroup's latest research report highlights that China's AI-driven drug discovery (AIDD) sector is accelerating rapidly, with the speed and cost advantages of AI drawing significant attention from the investment community. According to market research data, global pharmaceutical R&D investment is estimated at approximately $313 billion in 2026, yet AIDD penetration remains at only about 6%. The bank believes there is substantial room for industry expansion, projecting the global AI drug discovery ecosystem could reach around $50 billion by 2030, with growth concentrated across three key areas: data generation, wet-laboratory validation, and AI-native discovery.

Citigroup views INSILICO (03696) as a hybrid enterprise combining both platform capabilities and a robust pipeline. Its proprietary AIDD platform is expected to consistently produce "higher quality and more differentiated" clinical assets, potentially creating exponential value. The bank maintains a "Buy" rating on INSILICO (03696) with a target price of HK$85, designating it as the top pick in the sector. Regarding XtalPi Holdings (02228), Citigroup has initiated coverage with a target price of HK$8, noting that while the company integrates physical AI, robotic experimentation, and intelligent orchestration, the depth of its product pipeline remains limited, and commercial output is still pending further validation.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment